Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. / (Record no. 1166)

MARC details
000 -LEADER
fixed length control field 04297naa a22005897i 4500
001 - CONTROL NUMBER
control field UMUN-OA-20261005-MLS-024
003 - CONTROL NUMBER IDENTIFIER
control field local
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20261005174903.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr||||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 261005s2017 xx o u000 0 eng d
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/s12325-017-0612-x
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (local)EuropePMC:PMC5656728
040 ## - CATALOGING SOURCE
Original cataloging agency local
Language of cataloging eng
Transcribing agency local
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Gilles Salles
Relator term author.
245 10 - TITLE STATEMENT
Title Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. /
Statement of responsibility, etc. Gilles Salles; Martin Barrett; Robin Foà [and others].
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture [Place of publication not identified] :
Name of producer, publisher, distributor, manufacturer [publisher not identified],
Date of production, publication, distribution, manufacture, or copyright notice 2017.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (1 article).
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
500 ## - GENERAL NOTE
General note Publication type: Review article.
500 ## - GENERAL NOTE
General note Linked open-access copy: published version.
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open access; no subscription required for the linked open-access version.
Standardized terminology for access restriction Unrestricted online access
Source of term star
520 3# - SUMMARY, ETC.
Summary, etc. Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. Funding F. Hoffmann-La Roche Ltd., Basel, Switzerland.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons Attribution-NonCommercial. See the linked licence for the applicable terms.
Uniform Resource Identifier <a href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</a>
546 ## - LANGUAGE NOTE
Language note In English.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 ## - LOCAL NOTE (RLIN)
Local note Course allocation: B. Sc. Medical Laboratory Science.
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Safety
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Monoclonal antibody
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element CD20
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment outcome
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Follicular Lymphoma
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Rituximab
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term B. Sc. Medical Laboratory Science
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term UMUN open access collection
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term hematology
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Review articles.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Martin Barrett
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Robin Foà
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Joerg Maurer
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Susan O'Brien
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Nancy Valente
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Michael Wenger
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name David G Maloney
Relator term author.
773 0# - HOST ITEM ENTRY
Title Advances in therapy
Related parts Vol. 34, no. 10, (2017), pages/article 2232-2273
International Standard Serial Number 0741-238X
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://europepmc.org/articles/PMC5656728">https://europepmc.org/articles/PMC5656728</a>
Link text Read open-access publication
Public note Open access.
Access status 0
884 ## - DESCRIPTION CONVERSION INFORMATION
Conversion process Course selection and automated MARC21 enrichment from Europe PMC metadata.
Conversion date 20261005
Identifier of source metadata https://europepmc.org/articles/PMC5656728
Conversion agency local
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC No

No items available.